Phosphate binders and calcimimetic

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Phosphate binders and calcimimetic (brand names Renvela, PhosLo, Sensipar) — Chronic kidney disease mineral agents; Phosphate binders (sevelamer, calcium acetate); calcimimetic (cinacalcet).

Identification

• Therapeutic class: Chronic kidney disease mineral agents.
• Pharmacologic class: Phosphate binders (sevelamer, calcium acetate); calcimimetic (cinacalcet).

Pharmacology

• Mechanism of action: Phosphate binders bind dietary phosphate in the gut; cinacalcet increases sensitivity of the parathyroid calcium receptor to lower parathyroid hormone.
• Onset / peak / duration: Phosphate control over time; cinacalcet lowers parathyroid hormone over days.
• Half-life / therapeutic level: Variable; monitor calcium, phosphate, and parathyroid hormone.

Clinical use

• Indications: Hyperphosphatemia in chronic kidney disease (binders); secondary hyperparathyroidism (cinacalcet).
• Usual dose, route, frequency: Binders with each meal; cinacalcet PO daily with food.
• Maximum dose / adjustments: Titrate to phosphate, calcium, and parathyroid hormone.

Safety

• Contraindications: Bowel obstruction (binders); hypocalcemia (cinacalcet).
• Black box warning: None.
• Interactions: Binders reduce absorption of many oral drugs (separate doses); cinacalcet with CYP interactions.
• Pregnancy / lactation: Use if needed.
• High-alert: No.

Adverse effects

• Common side effects: GI upset, constipation or diarrhea; calcium acetate can raise calcium; cinacalcet causes nausea and hypocalcemia.
• Serious effects to report: Severe hypocalcemia (cinacalcet: numbness, tingling, muscle cramps, seizures), hypercalcemia (calcium acetate).
• Antidote / reversal: Calcium for cinacalcet hypocalcemia.

Nursing process

• Assessment before administration: Calcium, phosphate, parathyroid hormone.
• Interventions during therapy: Give binders with meals; monitor calcium closely with cinacalcet.
• Monitor: Calcium, phosphate, parathyroid hormone.
• Evaluation / expected outcome: Controlled phosphate and parathyroid hormone.

Patient teaching

• Patient teaching: Take binders with meals; report numbness or muscle cramps (cinacalcet).
• Notify provider if: Tingling, muscle cramps, seizures (low calcium), severe GI symptoms.
• Administration tips: Binders with food; separate other oral drugs.